Podcasts about combination therapy

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.

Drs Carol H. Wysham and Liana K. Billings discuss how to incorporate SGLT2 inhibitors and GLP-1 receptor agonists into the management of patients with type 2 diabetes and chronic kidney disease. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002049. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Global, Regional, and National Burden of Chronic Kidney Disease Due to Diabetes Mellitus Type 2 From 1990 to 2021, With Projections to 2036: A Systematic Analysis for the Global Burden of Disease Study 2021 https://pubmed.ncbi.nlm.nih.gov/40034386/ Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR https://pubmed.ncbi.nlm.nih.gov/36514729/ New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race https://pubmed.ncbi.nlm.nih.gov/34554658/ Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38785209/ Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://pubmed.ncbi.nlm.nih.gov/30990260/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 https://pubmed.ncbi.nlm.nih.gov/39651975/ CKD Early Identification & Intervention Toolkit https://kdigo.org/wp-content/uploads/2019/01/ISN_KDIGO_EarlyScreeningBooklet_WEB_updatedOct11.pdf Combination Therapy as a New Standard of Care in Diabetic and Non-Diabetic Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/39907542/ Living With Chronic Kidney Disease and Type 2 Diabetes Mellitus: The Patient and Clinician Perspective https://pubmed.ncbi.nlm.nih.gov/36282450/

This episode of Don't Miss a Beat centers on the evolving treatment landscape for transthyretin amyloid cardiomyopathy (ATTR-CM) with special guest Ahmad Masri, MD. Hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Steve Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, are joined by Masri, who serves as the director of the HCM and Amyloid Program at Oregon Health & Science University, to discuss the rapid therapeutic advances in ATTR-CM and the emerging questions shaping real-world clinical practice. Masri reviews the progression from a previously untreatable disease to one now managed with three US Food and Drug Administration (FDA)-approved disease-modifying agents: tafamidis (VYNDAMAX), acoramidis (Attruby), and vutrisiran (AMVUTTRA). He highlights the tafamidis approval in 2019 as a landmark in the field, showing a substantial survival benefit in the ATTR-ACT trial, followed by similar results from acoramidis, which received approval in late 2024, in ATTRibute-CM. Vutrisiran, a TTR gene silencer approved by the FDA in March 2025, represents a mechanistically distinct approach validated in the HELIOS-B trial. Despite these advances, Masri notes that patients with late-stage disease derive limited symptomatic benefit and that residual risk remains high, even with treatment. The conversation explores whether stabilizers and silencers can or should be combined, with Masri urging caution, citing the absence of clinical data demonstrating additive benefit and warning against assumptions of harmony without clinical evidence. Masri indicated ongoing trials, such as CARDIO-TTRansform, may offer clarity on this issue. Without direct comparisons between therapies, treatment selection often hinges on patient preference, delivery method, pill burden, and payer coverage. In practice, clinicians rely on pharmacodynamic markers, like changes in TTR levels, to assess treatment effect and adjust therapy accordingly. Masri emphasizes that while ATTR-CM trials may not show improvements in quality-of-life scores, slowing disease progression remains a critical and meaningful endpoint in this severe, high-mortality condition. Looking ahead, the panel discusses the next wave of therapeutic innovation. Multiple trials are now testing agents that aim to clear amyloid from the myocardium, including NI006 (ALXN2220), PRX004, and AT-02. These immune-modulating treatments are designed for long-term use and may complement stabilizers or silencers in patients with established amyloid burden. The episode closes with a discussion on prevention. For patients with asymptomatic cardiac involvement, current therapies halt disease progression entirely in many cases. For those with pathogenic TTR variants but no overt disease, surveillance is the current standard. However, Masri introduces the ACT Early trial, which will test whether early treatment with acoramidis can prevent the onset of clinical disease in high-risk individuals, potentially reshaping the paradigm of ATTR-CM care. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Key Episode Timestamps 00:00:00 Introduction and Guest Introduction 00:00:52 Current State of Amyloid Therapeutics 00:03:41 Introduction of New Stabilizers and Silencers 00:06:05 Combination Therapy and Clinical Data 00:10:36 Choosing Therapy for Patients 00:16:40 Disease Progression and Clinical Trials 00:20:28 Pipeline and Future Therapies 00:23:51 Preventative Therapy and Asymptomatic Patients 00:27:19 Conclusion and Future Directions

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

PEOPLE WORLDWIDE ARE SEARCHING FOR LONG-TERM RELIEF FROM CHRONIC ILLNESS. A CLINIC IN CYPRUS MAY HAVE THE ANSWER.info@apheresiscenter.eu         The Apheresis Center was founded to provide compassionate, cutting-edge care to those facing complex health challenges. Their journey began when Markus Klotz, one of the founders, experienced a severe case of Long COVID in 2020. After exhausting other options, he found hope through H.E.L.P. Apheresis in Germany with Dr. Beate Jaeger, becoming the first patient to receive what is now known as Combination Therapy. Inspired by his recovery, Markus and his friends, Constantinos Georgiou and Silke Fischer, partnered with Dr. Jaeger, B.Braun, and Mediprod to make this life-changing therapy accessible to others.https://info.apheresiscenter.eu/?utm_source=adwords&utm_medium=ppc&utm_campaign=DS%20%7C%20Pmax%20%7C%202023&utm_content=asset_group_4&utm_term&hsa_acc=7869943929&hsa_cam=20626355215&hsa_grp&hsa_ad&hsa_src=x&hsa_tgt&hsa_kw&hsa_mt&hsa_net=adwords&hsa_ver=3&gad_source=1&gbraid=0AAAAAqI_JZuGL6SI53CxIFsn0HNp2qPmw

Welcome back to today's Friday Review where I'll be breaking down the best of the week!     I'll be sharing specifics on these topics:     BPC-157  The 5 Tibetans (book review) Combination Therapy for Leukemia (AML) (research) Fluoride in Water (research)     For all the details tune in to today's Cabral Concept 3332 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3332 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125737 --- This podcast is supported by an educational grant from: AstraZeneca https://www.astrazeneca.com/our-therapy-areas/oncology.html With additional support from: Boston Scientific https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology.html --- SYNPOSIS Drs. Burgoyne and Mizrahi provide a primer on immunotherapy and explain how they communicate the principles of this treatment to their patients. Dr. Du discusses the Imbrave clinical trial and how recent studies have shown improved overall survival when immunotherapeutic agents are used, especially when multiple agents targeting various pathways are employed. When choosing between different regimens, the doctors consider factors such as the patient's underlying liver function, symptom burden, and prior treatments. Importantly, the doctors also discuss contraindications to immunotherapy, including a history of organ transplant, autoimmune disease, and poor performance status—all of which put patients at high risk for deterioration with this treatment. The treatment of patients with poor liver function remains controversial, as underlying cirrhosis may prevent the recovery of liver function. Dr. Berman outlines recent clinical trials studying the effects of transarterial chemoembolization (TACE) combined with immunotherapy. Finally, the doctors discuss the future of HCC treatment and the benefits of continued innovation in both interventional and medical oncology. --- TIMESTAMPS 00:00 - Introduction to Immunotherapy 04:32 - Notable Clinical Trials 13:39 - HCC Etiology and Immunotherapy Outcomes 18:43 - Contraindications for Immunotherapy 23:05 - Adverse Effects from Treatment 25:14 - Combination Therapy 36:22 - Considerations for Immunotherapy Dosing 40:26 - The Future of HCC Treatment --- RESOURCES Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, IMbrave150 Trial (Finn et al, 2020): https://pubmed.ncbi.nlm.nih.gov/32402160/ Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, HIMALAYA Trial (Abou-Alfa et al, 2022): https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial (Yau, 2022): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/abstract Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW (Galle, 2024): https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA4008 Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment (Llovet, 2022): https://pubmed.ncbi.nlm.nih.gov/35119481/ Find this episode on BackTable.com for more resources.

Iman Kashif from the University of Ottawa interviewed Dr. Barbara Vanderhyden, a senior scientist in ovarian cancer research and a professor at the University of Ottawa. In this insightful episode, Dr. Vanderhyden discusses her groundbreaking research pertaining to how immune regulator NLRC5 can reshape the tumor microenvironment and increase T-cell reactivity to better recognize and respond to cancer cells. She explains the mechanisms of immune evasion in ovarian cancer and discusses how her work could pave the way for novel therapeutic approaches. Learn more: https://www.ohri.ca/profile/vanderhydenlab/profile1:47 | Immune Evasion and NLRC5.4:49 | Clinical Applications of NLRC5.6:28 | Combination Therapy with NLRC5.9:23 | Tumor Adaptation Challenges. 12:26 | Advice for Early Career Professionals.Music Credit/Copyright information: Copyright free, Youtube video: “DEATH NOTE - L THEME SONG (RIFTI BEATS REMIX) [No Copyright Music]”. Account: Kingdom Power Music. Published January 18, 2021. https://www.youtube.com/watch?v=AkFHNQELp3Y&ab_channel=KingdomPowerMusicIman Kashif (Host, Audio Master), Jacqueline Aoun (Producer), Aaya Mahdi (Content Writer), Shreya Padhy (Content Writer)

In this podcast, a reproductive endocrinologist (Dr Sanjay K Agarwal) and patient advocate (Tara Mangum) provide their perspectives on the diagnosis and management of endometriosis. They also discuss Relugolix combination therapy as a treatment option for patients with endometriosis. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: [https://link.springer.com/article/10.1007/s12325-024-02970-2]. All conflicts of interest can be found online. This podcast is intended for medical professionals.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.  

Drs. Cesar Arias (@SuperBugDoc) and Katie Barber join Dr. Julie Ann Justo (@julie_justo) to discuss what is hot-off-the-presses for gram-positive bacterial infections and it's a total party vibe! They review the latest news for recent and ongoing clinical trials (DOTS, DISRUPT, and SNAP trials), discuss hope for novel clinical tests of the cefazolin inoculum effect in staphylococci, and explore the fascinating changes in virulence and potential therapeutic options for the most challenging enterococci. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References Climate Change and Antimicrobial Resistance. Editors in Conversation Podcast. American Society for Microbiology. Oct 2023. Is More Better? The Role of Combination Therapy for MRSA. Breakpoints Podcast Episode #30. Society of Infectious Diseases Pharmacists. Turner NA, et al. DOTS: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia. ESCMID Global 2024. April 2024. NCT04775953. Real-world dalbavancin observational cohort: Rebold N, et al. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. PMID: 38427289. Exebacase DISRUPT trial : Fowler VG Jr, et al. Clin Infect Dis. 2024 Jun 14;78(6):1473-1481. doi: 10.1093/cid/ciae043. PMID: 38297916. @snap_trial tweet of Breaking News. Aug 2024. Investigator Resources for the SNAP trial. Sept 2024: https://www.snaptrial.com.au/for-investigators#interim Cefazolin inoculum effect on mortality in MSSA bacteremia : Miller WR, et al. Open Forum Infect Dis. 2018 May 23;5(6):ofy123. doi: 10.1093/ofid/ofy123. PMID: 29977970. Prevalence of cefazolin inoculum effect in MSSA and modified rapid nitrocefin test for detection: Carvajal LP, et al. Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898-24. PMID: 39345182. LiaX as surrogate for cell envelope stress in Enterococus faecium: Axell-House DB, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106923. doi: 10.1128/aac.01069-23. PMID: 38289081. Shorter is better for uncomplicated streptococcal bacteremia: Clutter DS, et al. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0022024. doi: 10.1128/aac.00220-24. PMID: 38975753. Short vs. long antibiotic duration in Streptococcus pneumoniae bacteremia: Crotty M, et al. Open Forum Infect Dis. 2024 Aug 30;11(9):ofae478. doi: 10.1093/ofid/ofae478. PMID: 39257675. This podcast is powered by Pinecast.

Carbapenemase producers are a nightmare for clinicians. Not only are they resistant to carbapenems, a last resort β-lactam antibiotic, they are notorious for developing multidrug and pandrug resistances resulting in limited to no treatment options.  In this episode of Communicable, hosts Angela Huttner and Thomas Tängdén sit down with Dr. David Paterson (National University of Singapore) and Dr. Souha Kanj (American University of Beirut Medical Center, Lebanon), two ID physicians from regions where carbapenem-resistant Enterobacteriaceae or CRE, and carbapenem-resistant Acinetobacter are widespread.  The episode begins with the history and emergence of CRE and reviews current epidemiology, diagnosis (including the Ambler classification of β-lactamases) and treatment options. Lessons and insights from personal experiences are shared to reflect the current clinical challenges caused by carbapenem-resistant bacteria and the importance of infection prevention and control measures to mitigate further spread. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Filippo Medioli of Policlinico di Modena, Italy. For more related content on the WHO Priority Pathogens List and new antibiotics in the pipeline, check out our previous episodes, Communicable E3 and E10 (see Literature).Literature Communicable E3 - The New WHO Priority Pathogens List: which bugs to target first? June 2024. https://communicable.transistor.fm/episodes/communicable-e3-the-new-who-priority-pathogens-list-which-bacteria-to-target-first  Communicable E10 - Pipeline update: new antibiotics & other antimicrobials that you might actually use. Sep 2024. https://communicable.transistor.fm/episodes/communicable-e10-pipeline-update-new-antibiotics-other-antimicrobials-that-you-might-actually-use  Wagenlehner FM, et al. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N Engl J Med 2024 Feb. doi: 10.1056/NEJMoa2304748 Cohn J, et al. Accelerating antibiotic access and stewardship: a new model to safeguard public health. Lancet Infect Dis 2024 Sep. doi:  10.1016/S1473-3099(24)00070-7 Timsit JF, et al. When should I start broad-spectrum antibiotics? Intensive Care Med 2024 Sep. doi: 10.1007/s00134-024-07654-7  Paterson DL. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 2024 Apr. doi: 10.1080/13543784.2024.2326028 

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-399 Overview: In this episode, we look at a new study showing increased probability of survival for patients with Alzheimer disease (AD) who take donepezil and memantine together. We review current treatments for AD and address common hesitations in prescribing dual pharmacotherapy, providing vital insights for primary care clinicians. Episode resource links: Yaghmaei, E., Lu, H., Ehwerhemuepha, L. et al. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients.Commun Med 4, 99 (2024). https://doi.org/10.1038/s43856-024-00527-6 Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. PMID: 32914577; PMCID: PMC7667299. Guest: Jillian Joseph, MPAS, PA-C Music Credit: Richard Onorato Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-399 Overview: In this episode, we look at a new study showing increased probability of survival for patients with Alzheimer disease (AD) who take donepezil and memantine together. We review current treatments for AD and address common hesitations in prescribing dual pharmacotherapy, providing vital insights for primary care clinicians. Episode resource links: Yaghmaei, E., Lu, H., Ehwerhemuepha, L. et al. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients.Commun Med 4, 99 (2024). https://doi.org/10.1038/s43856-024-00527-6 Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. PMID: 32914577; PMCID: PMC7667299. Guest: Jillian Joseph, MPAS, PA-C Music Credit: Richard Onorato Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

While GLP-1 agonists continue to gain popularity in the medical management of diabetes and obesity, Dr. Cliff Weiss is exploring bariatric arterial embolization (BAE) as an adjunctive therapy to help patients sustain weight loss. Dr. Weiss, the Director of IR Research at Johns Hopkins, joins the show to discuss the techniques and impacts of BAE for obesity treatment. --- CHECK OUT OUR SPONSOR Reflow Medical https://www.reflowmedical.com/ --- SYNPOSIS Dr. Weiss outlines his initial research interest in gastric embolization of the fundus to reduce ghrelin production. He began by studying the use of sclerosants for embolization but later shifted to using embolic spheres. BAE involves the targeted embolization of the left gastric artery, with or without the left gastroepiploic artery, using 300-500 micron embolic spheres. Dr. Weiss also employs a dilute mixture of spheres and a vasodilator to achieve distal arterial penetration. He describes the role of BAE in conjunction with existing surgical and pharmaceutical treatments. According to his experience, patients undergoing BAE achieve maximum weight loss 6-9 months after the procedure and can maintain this weight when they follow up in a weight management clinic. Additionally, Dr. Weiss reviews data from BAE studies, including the BEAT Obesity Trial and the recent BEATLES Trial. --- TIMESTAMPS 00:00 - Introduction 03:21 - Early Research and Development of BAE 07:39 - Potential Role of BAE in Obesity Treatment 16:03 - Procedure Details 25:28 - Post-Procedure Care and Patient Management 28:06 - Insights from the BEAT Obesity Trial 33:38 - BEATLES Trial 37:38 - Combination Therapy for Obesity --- RESOURCES BEAT Obesity Trial: https://pubs.rsna.org/doi/full/10.1148/radiol.2019182354 LC Bead/Bead Block: https://www.bostonscientific.com/en-US/products/embolization/lc-bead.html EmboSpheres: https://www.merit.com/product/embosphere-microspheres/ EMBIO Trial: https://bmjopen.bmj.com/content/13/9/e072327 BEATLES Trial: https://www.jvir.org/article/S1051-0443(23)01155-7/fulltext

CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-in-cll-identifying-the-right-patient-for-the-right-treatment-approach/26498/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.

CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-for-cll-what-evidence-do-we-have/26497/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.

TruthStream links https://linktr.ee/truthstreamhttps://truthstream.cardiomiraclehealth.com/We are honored to welcome Dr Judy Mikovitsand Stanford Graham to the show 8/9/24 6pm PT 9pm ET. We will be #plandemic #cardiomiracle and much more. Plandemic documentary https://rumble.com/vq8e86-plandemic-documentary.html Interview with Stanford Graham https://rumble.com/v4jbv9u-truthstream-243-stanford-graham-athlete-lawyer-humanitarian-cardio-miracle-.html Interview with Dr David Martin https://rumble.com/v4wo1r6-dr-david-martin-humanity-12-senses-live-52424-6pm-pt-9pm-et.-truthstream-26.htmlHer website https://therealdrjudy.com Dr. Judy Mikovits earned a BA in Chemistry from University of Virginia in 1980 and a PhD in Biochemistry and Molecular Biology from George Washington University in 1992. In her forty-year quest to understand the causes, prevention and treatment of chronic diseases, she has co-authored seminal papers culminating at least a decade of research in each of four fields: Immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development. In 2009, Dr Judy Mikovits led the team that first isolated and characterized a new family of human disease-associated retroviruses, XMRVs. Dr Judy Mikovits has co-authored more than 50 peer reviewed publications and book chapters, and holds a patent for Combination Therapy for Prostate Cancer using Botanical Compositions and Casodex. Dr Judy Mikovits is a New York Times Best selling author of the books Plague, Plague of Corruption, Ending Plague and the Truth about the Masks. Her heart and passion is botanical drug development and personalized nutritional therapeutic solutions. Her current focus is education about the human endocannabinoid system and curative strategies for vaccine AIDS.

Got a show or guest idea? Send us a text!In this riveting episode of The Remedy Revolution, host Erin Paige delves into the dark and intricate history of bio weaponry and vectors with the esteemed Dr. Judy Mikovits. From shocking government coverups to the real-life implications of these hidden truths, Dr. Mikovits provides an expert's insight into the clandestine world of disease causation and prevention. The episode kicks off with a personal account from Erin Paige, recounting the severe health decline she and her son experienced in 2011 following a mosquito swarm attack, setting the stage for a deep dive into the underbelly of bioweapon research and its impacts.**Guest Bio:**Dr. Judy Mikovits is a renowned scientist with a BA in Chemistry from the University of Virginia (1980) and a PhD in Biochemistry and Molecular Biology from George Washington University (1992). Over her forty-year career, Dr. Mikovits has made significant contributions in several fields, including Immunology, natural products chemistry, epigenetics, and HIV/AIDS drug development. She is best known for leading the team that isolated and characterized a new family of human disease-associated retroviruses, XMRVs, in 2009.Dr. Mikovits has co-authored more than 50 peer-reviewed publications and book chapters and holds a patent for Combination Therapy for Prostate Cancer using Botanical Compositions and Casodex. She is a New York Times bestselling author with notable works such as "Plague," "Plague of Corruption," "Ending Plague," and "The Truth about the Masks." Her current focus lies in educating the public about the human endocannabinoid system and developing curative strategies for vaccine-induced AIDS.**Key Topics Discussed:**- The historical context and development of bio weaponry- The role of vectors in the spread of chronic diseases- Personal anecdotes of health crises related to bioweapons- Government coverups and misinformation campaigns- Insights from Dr. Mikovits' extensive research and publications and the ODEM educational platform- The importance of botanical drug development and personalized nutritional therapies**Call to Action:**Tune in to this eye-opening episode to gain a deeper understanding of the hidden truths behind bio weaponry and the ongoing quest for effective treatments. Don't forget to subscribe to The Remedy Revolution podcast for more groundbreaking discussions and expert insights.**Links and Resources:**- For all things Dr. Judy related, please visit: https://www.therealdrjudy.com-For more information about Erin Paige, visit: https://heartwinghealing.com**Subscribe and Follow:**- Follow us on [Instagram](https://www.instagram.com/remedyrevolutionpodcast) and [Twitter](https://twitter.com/remedyrev).**Support the Podcast:**If you enjoyed this episode, please leave a review and share it with your friends. Your support helps us continue to bring you insightful and informative content. Additionally, if you would like to support the podcast financially, it would be of significant help. None of the episodes are currently monetized and I do not earn any revenue from their production. See the link below.Support the Show.

Send us a Text Message.In this episode of 'The Nourished Nervous System,' I delve deeply into the world of herbs that support the nervous system. I share personal experiences and professional insights on five key herbs: Chamomile, Milky Oat Tops, Passionflower, Tulsi (Holy Basil), and Ashwagandha. I explore each herb's unique properties, benefits, and applications. Chamomile is celebrated for its calming effects on the gut and immune system, while Milky Oat Tops nourish the nervous system and ease stress. Passionflower helps to quiet a busy mind and combat insomnia, whereas Tulsi offers an uplifting, adaptogenic support. Lastly, Ashwagandha is highlighted for its rejuvenative qualities and its role in managing stress and anxiety. Practical tips for growing, sourcing, and using these herbs are provided, making this episode a rich resource for anyone interested in herbal remedies for nervous system health.In this episode:Herbal Education and ExperiencesUnderstanding Herbs and Their UsesNervous System Herbs and Personal FavoritesChamomile: The Gentle PowerhouseMilky Oats: The Soother of Frayed NervesPassionflower: Quiet that Busy MindTulsi: Sattva in Plant FormAshwagandha: The RejuvenatorRelated Episodes:Episode 15:  Vibrancy is a Long GameEpisode 51: Nourish Your Mind:  Ayurveda, Breath Work, and Seasonsal Self CareResources:Ayurvedic Nervous System Type QuizReferences:  Pole, S. (2013). Ayurvedic Medicine. Singing Dragon.Groves, M. N. (2016). Body into Balance. Storey Publishing.Ahn J, Ahn HS, Cheong JH, Dela Peña I. Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy. Neural Plast. 2016;2016:1320423. doi: 10.1155/2016/1320423. Epub 2016 Feb 4. PMID: 26966583; PMCID: PMC4757677.My resources:Deep Rest MeditationNourished For Resilience Workbook Book a free Exploratory CallFind me at www.nourishednervoussystem.comand @nourishednervoussytem on Instagram

Timothy Wilens, M.D., discusses new medications approved for ADHD and strategies to manage hard-to-treat and complex ADHD (attention deficit disorder plus at least one comorbid condition), including the use of a stimulant and nonstimulant medication. Treating Complex ADHD: More Resources Download: 2024 Scorecard of ADHD Treatments Sign Up: The Clinicians' Guide to Treating Complex ADHD Read: Treatment Troubleshooting Guide for Patients Replay: "Substance Use Disorder and ADHD: Safe, Effective Treatment Options," with Dr. Timothy Wilens Access the video and slides for podcast episode #508 here: https://www.additudemag.com/webinar/combination-therapy-comorbid-adhd-anxiety-depression/ Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.

Hypertension, commonly known as high blood pressure, is a silent yet prevalent health issue that affects millions of people worldwide. Often going unnoticed until significant damage has been done, hypertension can lead to severe cardiovascular complications if not properly managed. Mechanistically, the causes of hypertension are complex, involving both genetic and lifestyle factors. The management of hypertension presents multifaceted challenges, encompassing both pharmaceutical treatments and lifestyle modifications. From a prevention and management standpoint, understanding the interplay between genetics and lifestyle is crucial. This raises several important questions… To what extent do genetic factors contribute to hypertension risk compared to lifestyle choices, and how does this interaction influence disease progression? What role does lifestyle play in managing hypertension, and is there evidence supporting the influence of specific dietary patterns and nutrients, particularly sodium and potassium, on blood pressure control? How do exercise and physical activity impact blood pressure, and what types of exercise are most beneficial for individuals with or at risk of hypertension? What are the main categories of antihypertensive medications, and how do these drugs work to lower blood pressure? What are the potential side effects, and how should clinicians decide on the best treatment approach for individual patients? In this episode, we are joined by Dr. Mohammed Alo, a board-certified cardiologist and internal medicine specialist, who will help us understand the intricacies of hypertension and how it can be effectively controlled. Links: Go to episode page dralo.net/ Receive our free weekly email: the Sigma Synopsis Subscribe to Sigma Nutrition Premium Timestamps: 03:28 Dr. Alo's Background and Expertise 08:40 Understanding Blood Pressure and Its Implications 10:26 Causes and Diagnosis of High Blood Pressure 12:42 Lifestyle Modifications and Treatment Options 30:26 Medications for Blood Pressure Management 38:34 Combination Therapy and Patient Variability 43:11 Debunking Myths About Sodium and Blood Pressure 57:29 Exercise and Lifestyle Interventions

JACC: CardioOncology Deputy Editor Ronald Witteles, MD and Mazen Hanna, MD discuss some of the latest data from the 2024 International Society of Amyloidosis meeting.

Please visit answersincme.com/SWS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver cancer discusses emerging transarterial chemoembolization (TACE) plus immunotherapy–based combinations in intermediate-stage hepatocellular carcinoma (iHCC). Upon completion of this activity, participants should be better able to: Identify the limitations of currently available therapeutic approaches for patients with locoregional therapy–eligible, unresectable hepatocellular carcinoma (HCC); Describe the clinical significance of combination therapies that involve transarterial chemoembolization (TACE) and immunotherapy for patients with intermediate HCC (iHCC); and Review clinical strategies to integrate TACE plus immunotherapy–based combination regimens into the treatment paradigm for patients with iHCC, based on the preliminary data.

FSA's ELAP Extension Condition of the Kansas Wheat Crop Combination Therapy in Cattle   00:01:05 – FSA's ELAP Extension: Beginning today's show is Dennis McKinney, director of the Kansas Farm Service Agency, to discuss the expansion of the Emergency Livestock Assistance Program as well as the status of other FSA programs. Farmers.gov   00:12:05 – Condition of the Kansas Wheat Crop: K-State wheat production specialist Romulo Lollato keeps the show rolling as he explains the current condition of the wheat crop and addresses the freeze damage concern for wheat growers. 2024 Kansas Wheat Injury Symptoms from Freeze Damage to Wheat First Hollow Stem Update   00:23:05 – Combination Therapy in Cattle: The show winds up with K-State's Brad White, Katie Long and Brian Lubbers with another segment from the Beef Cattle Institute's Cattle Chat podcast as they talk about a literature review on combination therapy. BCI Cattle Chat Podcast Bovine Science with BCI Podcast Email BCI at bci@ksu.edu     Send comments, questions or requests for copies of past programs to ksrenews@ksu.edu.   Agriculture Today is a daily program featuring Kansas State University agricultural specialists and other experts examining ag issues facing Kansas and the nation. It is hosted by Shelby Varner and distributed to radio stations throughout Kansas and as a daily podcast.   K‑State Research and Extension is a short name for the Kansas State University Agricultural Experiment Station and Cooperative Extension Service, a program designed to generate and distribute useful knowledge for the well‑being of Kansans. Supported by county, state, federal and private funds, the program has county Extension offices, experiment fields, area Extension offices and regional research centers statewide. Its headquarters is on the K‑State campus in Manhattan

Commentary by Dr. Valentin Fuster

Why have we not found the cure for cancer yet? Neil deGrasse Tyson, Chuck Nice, and Gary O'Reilly explore paradigm shifts in cancer treatment, molecular biology, and a promising new cancer drug AOH1996 with City of Hope cancer researcher Dr. Linda Malkas. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free.Thanks to our Patrons Willie Bass, Nicholas A Jones, Edwin Goel, Joe Gibbs, Shane Alexander, Keith Goodman, and James Kuntz for supporting us this week.Photo Credit: Dr. Cecil Fox (Photographer), Public domain, via Wikimedia Commons

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2

In this solo episode, we dive into the topic of hormones and hormone therapy. Join Bree Luck as she explores the effects of hormones and discusses the various ways menopausal hormone therapy can alleviate side effects of perimenopause.    00:02 Welcome to Pause to Go 00:44 Hormones and Stress during the Holiday Season 01:46 Understanding Hormone Fluctuations 03:55 What is Menopausal Hormone Therapy? 04:47 Types of Estrogen Therapy 07:12 Combination Therapy with Estrogen and Progestogen 14:07 Bioidentical and Compound Hormone Therapies 19:20 Navigating Hormone Therapy and Finding What Works for You 19:57 Share Your Midlife Story 20:59 Thank You and Stay Curious References:  https://vajenda.substack.com/ https://www.webmd.com/menopause/menopause-hormone-therapy https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/menopausal-hormone-therapy   https://www.menopause.org/publications/clinical-practice-materials/bioidentical-hormone-therapy/what-is-custom-compounded-therapy-   Wanna connect with Bree? (I'm here for it!!!)   Find me on Instagram: https://www.instagram.com/awkwardsagemedia/   Find me on LinkedIn: https://www.linkedin.com/in/breeluck/   Awkward Sage Media: www.awkwardsage.com   The Lovely Unbecoming Coaching Services: Explore your Inner Role System with Bree https://calendly.com/awkwardsage/90-minute-session Want to Support the Pause to Go Podcast? Here are three ways: 1. Leave a written review on Apple Podcasts or drop 5 stars on Spotify 2. Send me a voice memo, letting me know your thoughts about the show 3. Buy me a coffee.  A little caffeine goes a long way to ignite midlife convos.      

We are going to combine all of our favorite topics  — red light therapy, the mitochondria and methylene blue  — into this brain-centric episode. We know that the brain is the most mitochondrial-dense tissue in the body and, thus, photobiomodulation (namely, near-infrared light) can have a very positive effect. We also know that most of the methylene blue ingested eventually accumulates in the brain, which is why it has countless brain-boosting benefits. However, when it comes to mitochondrial function it's a double-edged sword.   The health of your mitochondria can (of course) work for you or against you. And when the function of your mitochondria declines, it will likely show up in those tissues that are mitochondrial-dense (i.e., tissues that require the most amount of energy to function). Our nervous system is extremely energy-intensive and the brain is the king/queen of the nervous system. Thus, when mitochondrial dysfunction strikes, it hits the nervous system — and particularly the brain — hard. This largely explains why neurodegenerative diseases are an every-increasing presence in our modern-day world. While this may all seem like sobering and dire news, there is a silver lining that can put you back at ease. Again, while mitochondrial dysfunction can work against you, as long as you harness tactics that boost mitochondrial health (and, thus, inherently prevent, mitigate and sometimes even reverse mitochondrial dysfunction), then you are well on your way to staving off neurodegenerative disease. In today's episode, methylene blue takes center stage as we dig into the research to see how this spectacular salt can buoy your mitochondrial health and play a pivotal role in numerous neurodegenerative diseases. As always, light up your health! - Key Points:   Intro & Weather (00:00:00 - 00:02:25) Montana weather update and Dr. Mike's snow aversion   Holidays & BioLight Sale (00:02:25 - 00:03:24) Mention of approaching holidays Announcement of pre-Black Friday sale at BioLight   Upcoming Interviews & Office Hours (00:03:24 - 00:05:53) Encouragement to subscribe and introduction of Instagram Live office hours Details about the purpose, structure, and inaugural session of office hours Significance of two-way communication and bridging gaps in red light therapy education   Main Topic: Mitochondrial Dysfunction (00:12:03 - 00:15:14) Introduction and eagerness to explore mitochondrial dysfunction Consequences and treatment strategies discussed ​ Microtherapy and Treatment Strategies (00:18:24 - 00:21:19) Introduction to "microtherapy" and various treatments Announcement of an e-book   Mitochondria's Role in Health (00:21:19 - 00:24:16) Emphasis on overall health and lifestyle impact   Exploring Methylene Blue (00:24:16 - 00:26:54) Introduction to "From Mitochondrial Function to Neuroprotection" Historical background and BioLight product announcement   Methylene Blue's Mechanisms (00:26:54 - 00:30:05) Effectiveness, historical evolution, psychiatric applications, and MAOI function discussed   Mitochondrial Function and Methylene Blue (00:30:05 - 00:33:07) Importance of mitochondrial function and overview of the electron transport chain   Methylene Blue's Role in Mitochondrial Dysfunction (00:33:07 - 00:35:52) Promotion of complex four activity Tau aggregation in Alzheimer's   Methylene Blue in Alzheimer's and Parkinson's (00:35:52 - 00:37:12) Preservation of electron transport chain function Behavioral improvements in Parkinson's   Benefits and Combination Therapy (00:37:12 - 00:39:21) Potential benefits with levodopa and emphasis on investigating safety   Methylene Blue in Traumatic Brain Injury (00:39:21 - 00:40:01) Transition to TBI discussion Encouragement to use remedies promptly   Preclinical Studies on Methylene Blue (00:40:01 - 00:41:15) Overview of TBI studies and quick administration's impact on outcomes   Effectiveness of Methylene Blue (00:41:15 - 00:43:37) Studies showing effectiveness post-TBI Likelihood of combination therapy efficacy   Cognitive Enhancement and Aging (00:43:37 - 00:52:40) Exploration of cheaply available compounds and Methylene Blue's potential in cognitive enhancement Protection against age-related decline Neurogenesis and mitochondrial health   Conclusion and BioLight Product (00:52:40 - 00:55:53) Summary of article focus and BioLight's enhanced methylene blue product   Closing (00:55:58:15 - 00:56:53:08) Dr. Mike's recommendation to explore BioBlue Encouragement to share information - Articles referenced in the episode:   Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview   From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue - Learn more about methylene blue & BioBlue: Methylene blue​ ​BioBlue - Dr. Mike's #1 recommendations: Grounding products: Earthing.com EMF-mitigating products: Somavedic Blue light blocking glasses: Ra Optics - To learn more about red light therapy, methylene blue and shop for the highest-quality red light therapy products, visit https://www.biolight.shop - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Instagram YouTube Facebook

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including: Mechanisms of β-lactam resistanceEffect of resistance mechanism on susceptibility to antipseudomonal agent2023 IDSA guidance recommendations Activity against newer antipseudomonal β-lactams in the United StatesThe latest clinical data by antimicrobial regimen:              - Ceftolozane/tazobactam              - Ceftazidime/avibactam              - Imipenem/cilastatin/relebactam              - CefiderocolApplying antimicrobial stewardship principlesProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP  Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland  School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical Center|Baltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine  Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139Link to full program: https://bit.ly/40HyvPy 

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems Program Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/40Mmicz

Think you're all caught up on the latest psoriasis research? Think again. This week, we're joined by Dr. Brad Glick as he walks us through the importance of the skin barrier and how to support it, and offers tips on exciting combination therapies. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Brad P. Glick, DO FAOCD is a board-certified dermatologist practicing at the Glick Skin Institute in Margate and Wellington, Florida. Dr. Glick is also an Assistant Clinical Professor of Dermatology at Herbert Wertheim College of Medicine at Florida International University and Dermatology Residency Program Director at the Larkin Palm Springs Hospital, Miami, Florida. He is a member of the Board of Directors of the American Academy of Dermatology, Past President of the Florida Academy of Dermatology, Past President of the American Osteopathic College of Dermatology, and a member of the Medical Board of the National Psoriasis Foundation.

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Emily Atkins from The George Institute in Sydney, Australia. They discuss the use of low-dose combination medications for treating hypertension. If you enjoy the show, please leave us a podcast review at https://itunes.apple.com/gb/podcast/heart-podcast/id445358212?mt=2 Link to published paper: https://heart.bmj.com/content/early/2023/07/25/heartjnl-2022-322300 and https://www.sciencedirect.com/science/article/pii/S014067362101922X?via%3Dihub

Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights: Ryzumvi (Phentolamine Ophthalmic Solution) for Dilated Pupil Reversal The FDA has approved Ryzumvi for treating pharmacologically-induced mydriasis (dilated pupils). Ryzumvi, formerly known as Nyxol, will be available in the US in 2024 and is currently the only commercially available treatment for reversing dilated eyes. Exxua (Gepirone Hydrochloride) for MDD Exxua, an antidepressant, has received FDA approval for the treatment of major depressive disorder in adults. Exxua has faced regulatory challenges in the past. It works through selective agonism of 5HT1a receptors without causing common antidepressant side effects like sexual issues or weight gain. Likmez, Liquid Formulation of Metronidazole The FDA has approved Likmez, the only liquid oral suspension of metronidazole in the US. The liquid formulation provides an alternative for patients who struggle with the tablet version due to taste or swallowing difficulties. DNA Test for Hereditary Cancers The FDA granted marketing authorization for Invitae Common Hereditary Cancers Panel, a diagnostic test identifying genetic risks for certain cancers. This is the first FDA-approved test of its kind, with over 99.0% accuracy in detecting variants in 47 cancer-associated genes. Tofidence (Actemra [toclizumab] Biosimilar) Tofidence, a biosimilar referencing Actemra, has been approved by the FDA for certain rheumatologic indications. A biosimilar, it closely resembles the FDA-approved biologic Actemra in safety, purity, and efficacy. Pombiliti + Opfolda for Pompe Disease The FDA approved Pombiliti + Opfolda, a two-component therapy for adults with Pompe disease. The therapy shows significant improvements in patient mobility and is designed to address enzyme deficiency while maintaining it's efficacy in Pompe disease. Subcutaneous Entyvio (Vedolizumab) for Moderate-to-Severe Ulcerative Colitis The FDA has approved a subcutaneous form of Entyvio for maintenance therapy in adults with ulcerative colitis. Previously approved as an intravenous formulation, this subcutaneous version achieved significant clinical remission in trials for use as maintenance therapy. Experimental Stromal Cell Platform in Mild-To-Moderate ALS The FDA Advisory committee voted against the effectiveness of BrainStorm Cell Therapeutics' NurOwn stromal cell therapy for mild to moderate ALS. BrainStorm Cell Therapeutics plans to initiate a phase 4 study in 2024. Intro and outro music Garden Of Love by Pk jazz Collective    

In this episode, Tarik Asselah, MD, PhD, and Ira Jacobson, MD, provide expert insight on HDV screening, diagnosis, and management, including:Approach to screeningBarriers to screening (eg, test availability)Disease progression and complicationsDifferentiating between coinfection and superinfectionApproach to treatment (eg, whom to treat and when, treatment options, considerations for combination therapy)Management of patients with decompensated cirrhosisSurrogate markers to measure treatment successRole of correcting thrombocytopenia before initiating therapyFaculty:Tarik Asselah, MD, PhDProfessor of Medicine Department of HepatologyHôpital BeaujonUniversité de ParisClichy, FranceIra Jacobson, MDProfessor of MedicineNYU School of MedicineDirector of HepatologyDivision of Gastroenterology and HepatologyNYU Langone HealthNew York, New YorkLink to full program: https://bit.ly/3yp1Lxf 

In this episode, Nancy Reau, MD, and Heiner Wedemeyer, MD, provide expert insight on HDV management, including:Use of noninvasive imaging or biopsy for staging liver diseaseScreening for hepatocellular carcinomaHBV treatmentRole of comedications (eg, erythropoietin, eltrombopag)Approach to complex cases, such as patients with:Significant fibrosis and low HDV RNA levelsHepatitis delta antibody positivity, but HDV RNA negativityHIV coinfectionDecompensated or recently decompensated cirrhosisFaculty:Nancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisHeiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology and Endocrinology Hannover Medical SchoolHannover, GermanyLink to full program: http://bit.ly/3yp1Lxf

In this episode, we discuss rapid cycling bipolar disorder and its treatment, focusing on the use of the combination of lamotrigine and lithium. We also highlight the importance of checking thyroid status and tapering antidepressants in patients with rapid cycling. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 45 Lamotrigine and Lithium Combination for Treatment of Rapid Cycling Bipolar Disorder: Results From Meta-Analysis

In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:Gram-negative resistancePharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infectionsComparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremiaReal-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organismsAntimicrobial stewardshipSafety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFYThe SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIsData from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteriaInvestigational agentsOpen-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactamSummary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatmentPost hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs Faculty: David van Duin, MD, PhD, FIDSA, FAST Professor of Medicine Director, Immunocompromised Host Infecious Diseases Program Division of Infectious Diseases University of North Carolina Chapel Hill, North Carolina Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc. Link to full program: https://bit.ly/3niXGJ6Link to downloadable slides: https://bit.ly/3Hx0ppn

Several medication classes can be used to treat diabetic peripheral neuropathic pain (DPNP); however, many patients have a suboptimal response or experience dose-limiting side effects. Treatment guidelines suggest several first-line options but, in the absence of compelling evidence, offer no direction as to which agent to try first or if we should consider combination therapy. Guest Authors: Shilpa Klocke, PharmD, BCPS and Nicole Hahn, PharmD, BCACP Music by Good Talk

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:Barriers to HDV screening, including limitations to AASLD guideline recommendationsUse of double reflex testing to improve HDV diagnosisConsiderations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDVUpdated CDC recommendations for HBV screening for all adults using a triple panel test Staging advanced liver disease in patients with HDVIndications for HDV treatment, including patients with low ALT levels and advanced or progressive liver diseaseTreatment landscape for HDVPersonal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosisUpdates on novel HDV therapies, including:Summary of efficacy data on bulevirtide from clinical trialsInterpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib Link to full program: bit.ly/3yp1Lxf

LifeBlood: We talked about improving combination therapy, detecting cancer quickly and efficiently, and removing any roadblocks to proactive medical care, with Navid Alipour, Founder and CEO of AI Med Global. Listen to learn about the future of personalized care! You can learn more about Navid at AIMedGlobal.com, Facebook, Twitter and LinkedIn. To give the gift of CureMatch, enter CureMatchPodcast at checkout.  Thanks, as always for listening! If you got some value and enjoyed the show, please leave us a review here: ​​https://ratethispodcast.com/lifebloodpodcast You can learn more about us at LifeBlood.Live, Twitter, LinkedIn, Instagram, YouTube and Facebook or you'd like to be a guest on the show, contact us at contact@LifeBlood.Live.  Stay up to date by getting our monthly updates. Want to say “Thanks!” You can buy us a cup of coffee. https://www.buymeacoffee.com/lifeblood

Show notes at pharmacyjoe.com/episode761. In this episode, I'll discuss cefazolin and ertapenem combination therapy for refractory MSSA bacteremia. The post 761: Cefazolin and ertapenem combination therapy for refractory MSSA bacteremia appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode761. In this episode, I ll discuss cefazolin and ertapenem combination therapy for refractory MSSA bacteremia. The post 761: Cefazolin and ertapenem combination therapy for refractory MSSA bacteremia appeared first on Pharmacy Joe.